Navigation Links
Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
Date:2/26/2008

ourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. CardioDynamics Provides 2007 Shareholder Meeting Update
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic stem ... ("Cordlife"), a multi-product healthcare company catering to the mother and child ... assisting patients across the PRC, Singapore , ... India , the Philippines and ...
(Date:7/23/2014)... 23, 2014 Astra Nova ... comprehensive consultancy and pharma training services, and the ... (ACRES) , a non-profit integrating the expertise and ... maintain a global system for clinical trials, are ... improve the expertise of industry professionals through improved ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
(Date:7/22/2014)... Dallas, Texas (PRWEB) July 22, 2014 ... the growth and maintenance of cell culture. They allow ... meet the needs of researchers in drug discovery and ... extensively used in mAb production, iPSC research, cryobanking, cell-based ... and reduce contamination risk. , Analysts forecast the ...
Breaking Biology Technology:China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4
... Inc have successfully implemented Amphora,s PatentSafe solution to ... PatentSafe as a fully electronic lab notebook, with ... efficiently into today,s laboratories but it also allows ... and effectively, saving significant time previously spent on ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter,drugs in the People,s Republic of ... quarter and fiscal year ended December 31,2008. , , ... -- Total revenues increased 104.0% year-over-year to $26.0 ...
... Hovione is pleased to announce,that its licensee Daiichi ... use Hovione,s TwinCaps(R) dry powder inhaler device in ... neuraminidase inhibitor active,against the influenza virus. Daiichi Sankyo ... in Japan and other Asian countries and results,are ...
Cached Biology Technology:Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 2Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 2China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 4China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 5China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 6China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 7China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 8China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 9China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 10Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza 2Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza 3
(Date:7/23/2014)... around the world have no access to clean drinking ... million people die from water-related diseases every year. ETH ... a contribution to solving this problem. Working with researchers ... the Functional Materials Laboratory, the 23-year-old spent a year ... "What makes our DrinkPure filter unique is that you ...
(Date:7/23/2014)... release is available in German . ... stability to cells, drive metabolic processes and transmit signals. ... three-dimensional shapes. Scientists at the Max Planck Institute for ... can be constructed of similar amino acid chains even ... the proteins that exist today arose from common precursors. ...
(Date:7/23/2014)... (PHILADELPHIA) The Worldwide Innovative Networking in personalized cancer ... Kimmel Cancer Center at Thomas Jefferson University ... the only member of this prestigious group in the ... the delivery of innovative personalized medicine to the patient ... patient advocacy. , "Our participation in the WIN consortium ...
Breaking Biology News(10 mins):ETH student develops filter for clean water around the world 2Protein evolution follows a modular principle 2New partnership brings more personalized cancer treatment to Philadelphia 2
... Research from Queen,s University Belfast has revealed the 20th ... certainly associated with changes in farming practices. The ... Ireland last Tuesday (22nd June), but a recent study, ... published in the international journal Biological Conservation , ...
... U.S. Department of Energy has awarded a consortium of universities ... to $9 million over the next three years to conduct ... from algae a viable and competitive alternative to gasoline for ... funds are being supplemented by $3 million from a consortium ...
... brain, scientists can alleviate the effects of disorders such ... news. But because controlling that stimulation currently lacks ... of its therapeutic benefits for the patient over time. ... of a European consortium, is delving deep into human ...
Cached Biology News:Irish hares fall foul of modern farming trap 2DOE awards UC San Diego consortium $9 million for algal biofuels research 2A pacemaker for your brain 2
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
... XpressPack™ Colorimetric Detection System is intended for ... DNA generated by an in-house validated in ... target of interest. • ... is a hybridization capture assay designed to ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Biology Products: